ReviewMedicine2016

Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.

Zobair M Younossi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.